Abstract: Ovarian cancer is a malignant cancer with insidious onset, and it remains the leading cause of death from gynecological malignancies. Most ovarian cancer patients die of recurrences and drug-resistance. Poly ADP-ribose polymerase （ＰＡＲＰ） inhibitors emerge as a new class of targeted agents for ovarian cancer. PARP inhibitors can inhibit PARP enzyme as target in BRCA mutation-positive cells. With a number of clinical trials have shown, PARP inhibitors have anti-cancer effect on ovarian cancer with BRCA mutations. And the adverse effects are well tolerated. As clinical trials shown, PARP inhibitors prolong significantly the progress free survival of ovarian cancer patients with BRCA deficiency. In addition, PARP inhibitors are most active in platinum-sensitive, BRCA mutation-positive ovarian cancer. This review discusses the mechanism of PARP inhibitors as well as the clinical development of this class of anti-cancer agents in ovarian cancer treatment.

Key words: Poly（ＡＤＰ－ｒｉｂｏｓｅ） polymerases, Ovarian neoplasms, Genes，BRCA1, Genes，BRCA2, Drug therapy